I agree that this site is using cookies. You can find further informations here.
X
de Guibert, Sophie
348  results:
Search for persons X
?
1

Remission after CAR T‐cell therapy: Do lymphoma patients re..:

Perthus, Alya ; Colin, Fanny ; Charton, Emilie...
HemaSphere.  8 (2024)  5 - p. , 2024
Link: https://doi.org/10.1002/..
 
?
2

Impact of diagnostic investigations in the management of CA..:

Mauget, Matteo ; Lemercier, Sophie ; Quelven, Quentin...
Blood Advances.  8 (2024)  10 - p. 2491-2498 , 2024
Link: https://doi.org/10.1182/..
 
?
3

Blinatumomab after R-CHOP bridging therapy for patients wit..:

Guièze, Romain ; Ysebaert, Loïc ; Roos-Weil, Damien...
Nature Communications.  15 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
4

Long-term outcomes of patients with large B-cell lymphoma t..:

Oluwole, Olalekan O. ; Forcade, Edouard ; Muñoz, Javier...
Bone Marrow Transplantation.  59 (2024)  3 - p. 366-372 , 2024
Link: https://doi.org/10.1038/..
 
?
5

Prophylactic Corticosteroid Use with Axicabtagene Ciloleuce..:

Oluwole, Olalekan O. ; Forcade, Edouard ; Muñoz, Javier...
Transplantation and Cellular Therapy.  29 (2023)  2 - p. S379-S380 , 2023
Link: https://doi.org/10.1016/..
 
?
6

Prolonged thrombocytopenia after CAR T-cell therapy: the ro..:

Drillet, Gaëlle ; Lhomme, Faustine ; De Guibert, Sophie..
Blood Advances.  7 (2023)  4 - p. 537-540 , 2023
Link: https://doi.org/10.1182/..
 
?
7

P1687: LIFE AFTER CAR T-CELLS: DO PATIENTS RECOVER A NORMAL..:

Perthus, Alya ; Colin, Fanny ; Charton, Emilie...
HemaSphere.  7 (2023)  S3 - p. e725933e , 2023
Link: https://doi.org/10.1097/..
 
?
8

P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) ..:

Munir, Talha ; Shadman, Mazyar ; Robak, Tadeusz...
HemaSphere.  7 (2023)  S3 - p. e15364af , 2023
Link: https://doi.org/10.1097/..
 
?
9

P1407: REMOTE MONITORING OF CAR T-CELL TREATED PATIENTS BY ..:

Colin, Fanny ; Adeline, Bellec ; Le Bars, Laetitia...
HemaSphere.  7 (2023)  S3 - p. e8503646 , 2023
Link: https://doi.org/10.1097/..
 
?
10

A fixed-duration immunochemotherapy approach in CLL: 5.5-ye..:

Michallet, Anne-Sophie ; Letestu, Rémi ; Le Garff-Tavernier, Magali...
Blood Advances.  7 (2023)  15 - p. 3936-3945 , 2023
Link: https://doi.org/10.1182/..
 
?
11

Prophylactic Corticosteroid Use with Axicabtagene Ciloleuce..:

Oluwole, Olalekan O. ; Forcade, Edouard ; Muñoz, Javier...
Transplantation and Cellular Therapy.  28 (2022)  3 - p. S9 , 2022
Link: https://doi.org/10.1016/..
 
?
12

Prophylactic Steroid Use with Axicabtagene Ciloleucel (Axi-..:

Oluwole, Olalekan O. ; Bouabdallah, Krimo ; Muñoz, Javier...
Transplantation and Cellular Therapy.  27 (2021)  3 - p. S68 , 2021
Link: https://doi.org/10.1016/..
 
?
13

Poster: ABCL-339: Clinical Activity of Loncastuximab Tesiri..:

Janakiram, Murali ; Depaus, Julien ; Wagner-Johnston, Nina...
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  - p. S238 , 2021
Link: https://doi.org/10.1016/..
 
?
14

Real-world outcomes following venetoclax therapy in patient..:

Bouclet, Florian ; Calleja, Anne ; Dilhuydy, Marie-Sarah...
Annals of Hematology.  100 (2021)  4 - p. 987-993 , 2021
Link: https://doi.org/10.1007/..
 
?
15

ABCL-339: Clinical Activity of Loncastuximab Tesirine (Lonc..:

Janakiram, Murali ; Depaus, Julien ; Wagner-Johnston, Nina...
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  - p. S392 , 2021
Link: https://doi.org/10.1016/..
 
1-15